Pfizer innovative medicine AI Bo Xin was approved in China for the treatment of advanced breast cancer.

category:Society click:552
 Pfizer innovative medicine AI Bo Xin was approved in China for the treatment of advanced breast cancer.


Data show that breast cancer is the most serious threat to the health of women worldwide. In 2015, the number of new cases of breast cancer in China reached 272 thousand, and about 70 thousand cases died. The situation of advanced breast cancer is more severe. Each year, 1 of the 10 new patients have been diagnosed as advanced, and 30%-40% will develop into advanced breast cancer among early breast cancer patients who have undergone surgical and standardized treatment. Different from the diversification of early breast cancer treatment methods, in recent 10 years, there is no significant progress in the treatment of advanced breast cancer in China, the lack of breakthrough innovative therapy. ALB is suitable for the treatment of hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer. It should be used with aromatase inhibitors as an initial endocrine therapy for postmenopausal women. The global registry study showed that albosine combined with letrozole prolonged the median progression-free survival of patients with advanced breast cancer by 10 months compared with letrozole alone. The US Food and Drug Administration (FDA) approved a breakthrough new drug for the treatment of advanced breast cancer in 2013, which was approved by a rapid approval procedure in 2015. So far, AI Bo has been approved in 86 countries and regions in the world, China is the eighty-seventh. Source: Beijing News Editor: Ji Xue Ying _NN6784

Data show that breast cancer is the most serious threat to the health of women worldwide. In 2015, the number of new cases of breast cancer in China reached 272 thousand, and about 70 thousand cases died. The situation of advanced breast cancer is more severe. Each year, 1 of the 10 new patients have been diagnosed as advanced, and 30%-40% will develop into advanced breast cancer among early breast cancer patients who have undergone surgical and standardized treatment. Different from the diversification of early breast cancer treatment methods, in recent 10 years, there is no significant progress in the treatment of advanced breast cancer in China, the lack of breakthrough innovative therapy.

ALB is suitable for the treatment of hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer. It should be used with aromatase inhibitors as an initial endocrine therapy for postmenopausal women. The global registry study showed that albosine combined with letrozole prolonged the median progression-free survival of patients with advanced breast cancer by 10 months compared with letrozole alone.

The US Food and Drug Administration (FDA) approved a breakthrough new drug for the treatment of advanced breast cancer in 2013, which was approved by a rapid approval procedure in 2015. So far, AI Bo has been approved in 86 countries and regions in the world, China is the eighty-seventh.